WraSer Pharmaceuticals
WraSer Pharmaceuticals is a privately held specialty pharmaceutical marketing and distribution company that sells five niche branded prescription products in cardiovascular, otic, and pain management to physicians, pharmacies, and wholesalers across four U.S. regions.
- Company typePrivate
- Founded2002
- HeadquartersRidgeland, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What WraSer Pharmaceuticals does
WraSer Pharmaceuticals is an independent, privately held specialty pharmaceutical marketing and distribution company founded in 2002 and headquartered at 121 Marketridge Road, Ridgeland, Mississippi. The company identifies, develops, and markets proprietary branded prescription products to physicians, pharmacies, and wholesaler distributors across the Southwestern, Southeastern, Mid-West, and Mid-Atlantic regions of the United States.
The company's commercial portfolio consists of five niche branded prescription products across three therapeutic areas: cardiovascular (Zontivity, indicated for reduction of serious cardiovascular events in combination with aspirin/clopidogrel, with a boxed bleeding-risk warning), otic infections (Cetraxal, a preservative-free ciprofloxacin otic solution 0.2%; and Otovel, a ciprofloxacin/fluocinolone acetonide combination for acute otitis media with tympanostomy tubes in children six months and older), and pain management (Trezix, a CIII semi-synthetic opioid carrying extensive boxed warnings; and Nalfon, an NSAID/fenoprofen). These products are supported by dedicated product websites, prescribing information, and digital copay coupon programs for the otic franchise.
WraSer operates a sales-led go-to-market model with three primary channels: direct physician sales, retail/specialty pharmacy distribution, and wholesaler distribution in its four operating U.S. regions. The company is privately held with no disclosed parent company, institutional investors, or funding rounds; leadership includes President Heath Wray and CFO Ken Martin. Revenue, headcount trend, ownership structure, and financial performance are not publicly disclosed.
WraSer Pharmaceuticals firmographics
Firmographics- Name
- WraSer Pharmaceuticals
- Legal name
- WraSer Pharmaceuticals
- Website
- https://wraser.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- WraSer Pharmaceuticals is a privately held specialty pharmaceutical marketing and distribution company that sells five niche branded prescription products in cardiovascular, otic, and pain management to physicians, pharmacies, and wholesalers across four U.S. regions.
- Ownership category
- akta.pro rank
WraSer Pharmaceuticals industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- OTC & Consumer Health Distributors (HLAIAJAC)
- akta.pro secondary industry
- Ophthalmic & Otic Generics (HLAIABAF)
Keywords
Where WraSer Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Ridgeland
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
WraSer Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Marketing or Sales, Personnel, Operations, Technology or R&D, Infrastructure
Revenue model
- Branded Prescription Pharmaceutical Products: Revenue generated through the sale of proprietary branded prescription pharmaceutical products including cardiovascular medications (Zontivity), pain management drugs (Trezix, Nalfon), and otic treatments (Cetraxal, Otovel). Products are marketed and distributed to physicians, pharmacies, and wholesaler distributors across specific U.S. regions.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels3 records
WraSer Pharmaceuticals product offering
Product offeringCore offering
WraSer Pharmaceuticals is an independent specialty pharmaceutical company that identifies, develops, and markets proprietary branded prescription products to physicians, pharmacies, and wholesaler distributors in the Southwestern, Southeastern, Mid-West, and Mid-Atlantic regions of the United States. Its portfolio consists of five niche branded prescription products spanning three therapeutic areas: cardiovascular (Zontivity), otic infections (Cetraxal, Otovel), and pain management (Trezix, Nalfon).
Product overview
WraSer Pharmaceuticals is an independent specialty pharmaceutical marketing and distribution company offering a portfolio of five niche branded prescription products. The company focuses on three therapeutic areas: cardiovascular (Zontivity), OTIC/ear infections (Cetraxal, Otovel), and pain management (Trezix, Nalfon). These products are distributed to physicians, pharmacies, and wholesaler distributors across the Southwestern, Southeastern, Mid-West, and Mid-Atlantic regions of the United States.
Differentiator
Problem solved
Functional benefit
Products and services
- Zontivity Zontivity is a branded prescription antiplatelet medication used with aspirin, clopidogrel (Plavix), or both to reduce the risk of serious cardiovascular events such as heart attack, stroke, or death in appropriate patients; it carries a boxed warning for bleeding risk and is prescribed by physicians.
- Trezix Trezix is a CIII semi-synthetic opioid (dihydrocodeine/acetaminophen/caffeine) branded prescription product used for moderate to moderately severe pain relief when non-opioid alternatives are inadequate; it carries multiple FDA boxed warnings including addiction, abuse, misuse, life-threatening respiratory depression, hepatotoxicity, and neonatal opioid withdrawal syndrome.
- Nalfon Nalfon (fenoprofen calcium) is a branded prescription NSAID used to relieve mild to moderate pain and to reduce pain, swelling, and joint stiffness associated with arthritis; it is prescribed by physicians for patients requiring non-opioid anti-inflammatory therapy.
- Cetraxal Cetraxal (ciprofloxacin otic solution) 0.2% is a branded prescription sterile, preservative-free otic antimicrobial solution packaged in single-use 0.25 mL containers delivering 0.5 mg of ciprofloxacin, indicated for otic use in patients with ear infections.
- Otovel Otovel (ciprofloxacin and fluocinolone acetonide) is a branded prescription otic combination product used in children 6 months of age and older with tympanostomy tubes to prevent excess middle-ear fluid and to treat acute otitis media with tympanostomy tubes (AOMT) caused by susceptible bacteria.
Companies that use WraSer Pharmaceuticals
Customer profileSegments3 records
Ideal customer profiles2 records
WraSer Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
WraSer Pharmaceuticals partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights5 records
WraSer Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Arbor Pharmaceuticals: US specialty pharmaceutical company that markets branded prescription products across multiple therapeutic areas through physician and pharmacy channels — directly comparable independent specialty pharma commercial model.
- Vertical Pharmaceuticals (Tris Pharma affiliate): Specialty pharma company focused on branded prescription products distributed to physicians and pharmacies in defined US therapeutic niches — highly comparable GTM and product-portfolio approach to WraSer.
- Assertio Therapeutics: Specialty pharmaceutical company marketing branded pain and neurology prescription products to physicians and pharmacies — directly comparable therapeutic focus and specialty distribution model.
- ANI Pharmaceuticals: Specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription products — comparable scale, product breadth, and physician/pharmacy distribution strategy.
Broad incumbents
- Endo International: Larger established specialty pharmaceutical company with significant pain management and specialty branded Rx franchises — directly overlapping Trezix/Nalfon therapeutic categories at greater scale.
- Supernus Pharmaceuticals: Established specialty pharma focused on CNS and branded prescription products marketed through physician channels — broader portfolio but comparable niche-branded commercial model.
- Mallinckrodt Pharmaceuticals: Larger specialty pharmaceutical company with branded prescription products in pain, autoimmune, and specialty therapeutic areas — overlapping therapeutic focus at significantly greater commercial scale.
- Bausch Health (Valeant): Large diversified pharmaceutical company with specialty branded prescription franchises including cardiovascular and pain products — broad incumbent with overlap on WraSer's Zontivity/Trezix positioning.
Emerging players
- Mayne Pharma: Specialty pharmaceutical company with a mix of branded and generic prescription products sold through US physician and pharmacy channels — similar therapeutic breadth and specialty distribution model.
- Pernix Therapeutics: Smaller specialty pharmaceutical company historically focused on pain management and CNS prescription products marketed to physicians — comparable therapeutic emphasis and specialty commercial footprint.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
WraSer Pharmaceuticals social profiles
Digital presenceWraSer Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
WraSer Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles2 records
WraSer Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
WraSer Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about WraSer Pharmaceuticals
What does WraSer Pharmaceuticals do?
WraSer Pharmaceuticals is an independent specialty pharmaceutical company that identifies, develops, and markets proprietary branded prescription products to physicians, pharmacies, and wholesaler distributors in the Southwestern, Southeastern, Mid-West, and Mid-Atlantic regions of the United States. Its portfolio consists of five niche branded prescription products spanning three therapeutic areas: cardiovascular (Zontivity), otic infections (Cetraxal, Otovel), and pain management (Trezix, Nalfon).
Is WraSer Pharmaceuticals a public or private company?
WraSer Pharmaceuticals is a private company. It is classified as unknown and is currently operating.
When was WraSer Pharmaceuticals founded?
WraSer Pharmaceuticals was founded in 2002. It employs 51 to 100 people.
Where is WraSer Pharmaceuticals based?
WraSer Pharmaceuticals is headquartered in Ridgeland, United States, in the North America region.
How does WraSer Pharmaceuticals make money?
One revenue line is on record: branded Prescription Pharmaceutical Products.
Who are WraSer Pharmaceuticals's main competitors?
Direct peers on record are Arbor Pharmaceuticals, Vertical Pharmaceuticals (Tris Pharma affiliate), Assertio Therapeutics and ANI Pharmaceuticals. Broad incumbents are Endo International, Supernus Pharmaceuticals, Mallinckrodt Pharmaceuticals and Bausch Health (Valeant). Emerging players are Mayne Pharma and Pernix Therapeutics.
Does WraSer Pharmaceuticals have an API?
No public API is recorded for WraSer Pharmaceuticals.
What industry is WraSer Pharmaceuticals in?
WraSer Pharmaceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAJAC, OTC & Consumer Health Distributors, with a secondary code of HLAIABAF, Ophthalmic & Otic Generics. Its NAICS code is 424210 and its SIC code is 5122.